Headline dashboardThe half in numbers

The two quarters tell the concentration story: Q2 volume fell 11% yet total value rose 12% and the median jumped 31%, while average upfront per deal declined 11%. Value is pooling into fewer, larger deals, with the typical transaction getting bigger even as Q1’s outsized upfront commitments moderated.

Deal typeM&A retook the lead as upfront doubled

M&A and licensing generated comparable headline value in H1 but on entirely different economics. M&A produced $188.1 billion across 301 transactions, up 96% year-over-year, while licensing and options generated $178.5 billion across 241 deals, up 43%. On announced value the two are near-parity; on cash paid at signing they diverge sharply. M&A settled roughly 75 cents of every announced dollar upfront, against licensing’s 6 cents, the balance deferred into milestones and royalties. Divestitures held at $15.6 billion (66 deals) and commercialization deals at $1.7 billion.

The quarters sharpened the split. In Q2 2026, M&A generated $105.5 billion across 161 deals with $78.9 billion committed upfront, while licensing produced $90.2 billion across 104 deals but paid just $5.6 billion at signing. The pattern held across the half: acquirers deployed real capital for de-risked assets, while licensors structured early-stage bets around contingent value. Roche committed $700 million upfront against $2.3 billion for Nurix’s CBL-B degrader, a 30% upfront ratio that signals genuine conviction, while at the other end SK Biopharmaceuticals licensed Insilico’s AI-designed CNS portfolio for $4.5 million against $2.6 billion, a 0.2% ratio of maximum optionality and minimal commitment.

The deals that defined H1Anatomy of the five largest

Five transactions framed the half. The two biggest were China-sourced licensing pacts built on modest upfronts and enormous contingent value; the next three were cash acquisitions carrying full premiums for assets with data behind them.

The rankingThe 20 largest deals of H1 2026

The half’s twenty largest transactions span every sector DealFlow tracks. Biopharma dominates by count, but medtech holds three of the top twenty (including the third-largest deal overall) and diagnostics one, evidence that the largest capital in healthcare is no longer moving in drugs alone.

MomentumBeneath the monthly noise, a rising market

Monthly deal value is lumpy by nature; a single acquisition can define a month, as three did in June. The trailing-twelve-month view strips that noise out, and it points one way. Rolling deal value climbed from $611 billion at the start of 2026 to $752 billion by June, up roughly 23% in six months, and now exceeds the entire FY2025 total.

Cross-borderChina exports, the West buys

The single most important structural fact of the half is a trade route. Western companies in-licensed $92.6 billion across 45 deals from Chinese biotechs in H1, roughly 24% of all deal value, while Greater China as a buyer accounted for just $13.3 billion. China builds pipelines that are deep, fast and comparatively cheap, and monetizes them globally through out-licensing rather than commercializing abroad; Western buyers gain de-risked, clinical-stage assets at a discount to home-grown equivalents.

The two largest deals of the half, AstraZeneca’s CSPC pact and BMS’s Hengrui alliance, were both China-sourced, as were Pfizer’s and Lilly’s Innovent deals and AbbVie’s RemeGen agreement. The open question for H2 is whether policy friction, on IP, biosecurity or pricing, slows a flow that for now only accelerates.

MedtechConsolidation ran on cardiovascular and AI

Medtech was not a sideline in H1; it held three of the ten largest deals in all of healthcare and life sciences. The activity concentrated on two themes. In cardiovascular and structural heart, Boston Scientific acquired Penumbra for $14.5 billion and secured a $4.5 billion option over MiRus’s next-generation TAVR platform ($1.5 billion upfront, $3 billion on exercise); Medtronic added SPR Therapeutics ($650 million, peripheral nerve stimulation) and CathWorks ($585 million, AI coronary assessment); and Stryker bought Amplitude Vascular ($830 million, intravascular lithotripsy). In diagnostics and AI, Danaher acquired Masimo for $9.9 billion in patient monitoring, Roche bought PathAI for digital pathology, and Agilent added Biocare Medical for $950 million. The common thread is capability consolidation: the medtech majors are buying differentiated cardiovascular technology and AI-enabled diagnostics rather than chasing scale.

Venture & IPOFlat venture, a reopening public window

Company financing held steady while the public window cracked open. Venture raised $24.6 billion across 546 rounds in H1, near-flat on capital but in fewer, larger rounds, with growth-stage financing doing more of the work. The sharper signal is public: biotech IPOs raised $7.9 billion across 42 listings, up 136% on H1 2025, after a two-year freeze.

Therapy areasOncology leads; the specialties are rotating

Cancer anchored the half at $144.6 billion in deal value, up 66%, close to 40% of the market, and featured in the Hengrui, Pfizer-Innovent, GSK-Nuvalent, Gilead-Arcellx and Gilead-Tubulis deals. Neurology followed at $45.5 billion (+44%), autoimmune at $28.4 billion (+37%). The sharper signal sits below the leaders: dermatology deal value rose more than fivefold and ophthalmology nearly fourfold as capital rotated into specialty areas, while endocrine and metabolic cooled 11% after two frenzied years, even as it hosted the single largest licensing pact (CSPC-AstraZeneca).

Technology & modalityDrugs, devices, diagnostics and AI, in one market

Viewed across the full healthcare and life sciences scope, the half’s platform activity spans well beyond drug modalities. Small molecules led at $102.1 billion (+56%), but the momentum belongs to the platform layer and the wider sectors: AI and ML discovery rose 180% to $58.1 billion across 132 deals, now the second-largest technology category; medical devices reached $29.8 billion (+210%, 68 deals) and diagnostics $16.2 billion (+95%, 33 deals). Cell therapy jumped ninefold off a small base, ADCs held steady at $14.7 billion, and digital health, though high in volume at 27 deals, remained modest in disclosed value at $3.0 billion, concentrated in telehealth and care-delivery consolidation.

Most activeLilly ran away with it

Eli Lilly was the half’s defining dealmaker by a wide margin, signing 26 transactions worth roughly $54 billion across 11 acquisitions ($25 billion, including Centessa, Kelonia and others) and 15 licensing deals ($29.2 billion, including two Innovent pacts). Where Lilly led on breadth, others led on size: Gilead concentrated $15.4 billion into a handful of oncology and cell-therapy moves, Boston Scientific committed $19 billion across Penumbra and MiRus, and BMS led licensees at $16 billion.

The readWhat the first half is telling us

The half’s signal is concentration. Capital pooled into fewer, larger, cash-heavy deals aimed at assets that have already cleared meaningful risk, whether de-risked biotech pipelines, commercial-stage medtech, or Chinese clinical assets available at a discount. Buyers paid up, premiums of 24% to 49%, for certainty, and hedged everything earlier-stage through milestone-laden licensing increasingly sourced from China. Oncology remained the prize, obesity anchored the largest pacts, AI-enabled discovery was the fastest-rising route in, and medtech proved that the biggest capital in healthcare no longer moves in drugs alone.